Cargando…
Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations
INTRODUCTION: Recently, increasing FcRn binding by Fc engineering has become a promising approach for prolonging the half-life of therapeutic monoclonal antibodies (mAbs). This study is the first to investigate the optimization of an allometric scaling approach for engineered mAbs based on cynomolgu...
Autores principales: | Haraya, Kenta, Tachibana, Tatsuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709760/ https://www.ncbi.nlm.nih.gov/pubmed/36449140 http://dx.doi.org/10.1007/s40259-022-00566-2 |
Ejemplares similares
-
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody
por: Maeda, Atsuhiko, et al.
Publicado: (2017) -
In Translation: FcRn across the Therapeutic Spectrum
por: Qi, Timothy, et al.
Publicado: (2021) -
Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
por: Valente, Delphine, et al.
Publicado: (2020) -
Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
por: Lledo‐Garcia, Rocio, et al.
Publicado: (2021) -
Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
por: Ramdani, Yanis, et al.
Publicado: (2022)